CMAJ • May 22, 2007; 176 (11). doi:10.1503/cmaj.1070022.
© 2007 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falcone, E. L.
Right arrow Articles by Tangri, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Falcone, E. L.
Right arrow Articles by Tangri, N.

Letters

Drug-eluting stents

E. Liana Falcone* and Navdeep Tangri{dagger}

Medical Student, McGill University, Montréal, Que.;* Internal Medicine Resident (PGY-3), Clinician Investigator Program, McGill University, Montréal, Que.{dagger}

In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.1 They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the study authors recommended against the widespread use of drug-eluting stents. However, we believe that previously published cost analyses of drug-eluting stents, including those mentioned by Ligthart and associates, may have failed to consider the potential costs of lifetime therapy with clopidogrel.

Recent evidence suggests that cessation of clopidogrel therapy in patients with drug-eluting stents can lead to severe adverse outcomes such as in-stent thrombosis and may pose an increased mortality risk.2 As a result, the duration of clopidogrel therapy in these patients has become controversial, leading most physicians to treat these patients indefinitely. A cost analysis of 1 year of clopidogrel therapy in the PCI-CURE and CREDO trials showed diminishing returns after 4 weeks of therapy and that an expenditure ranging from $70 000 to $350 000 was required to avoid a single myocardial infarction.3

Given that the only proven benefit of drug-eluting stents over conventional bare-metal stents is the reduction in target vessel restenosis,4 we feel that the additional cost of lifetime clopidogrel therapy makes drug-eluting stents even less desirable. In a publicly funded health care system with limited resources, such as ours, interventions that provide marginal benefit at a high cost should be carefully scrutinized.

REFERENCES

  1. Ligthart S, Vlemmix F, Dendukuri N, et al. The cost-effectiveness of drug-eluting stents: a systematic review. CMAJ 2007;176(2):199-205.[Abstract/Free Full Text]
  2. Eisenstein EL, Anstrom KI, Dong KF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297(2):159-68.[Abstract/Free Full Text]
  3. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "emperor's new clothes" revisited. Eur Heart J 2004;25(9):720-2.[Free Full Text]
  4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346(23):1773-80.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falcone, E. L.
Right arrow Articles by Tangri, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Falcone, E. L.
Right arrow Articles by Tangri, N.